Current Treatment Options, Including Diet, Exercise, and Medications: The Impact on Histology

Mazen Noureddin; Manal F. Abdelmalek

doi:10.1016/j.cld.2023.01.008

Current Treatment Options, Including Diet, Exercise, and Medications: The Impact on Histology

Mazen Noureddin, Manal F. Abdelmalek

Houston Methodist

Research output: Contribution to journal › Review article › peer-review

Abstract

Paralleling the rise in obesity and diabetes, nonalcoholic fatty liver disease (NAFLD) is now the most prevalent chronic liver disease worldwide. Nonalcoholic steatohepatitis (NASH), the progressive form of NAFLD, may progress to cirrhosis, hepatic decompensation, and hepatocellular carcinoma. Despite its public health treat, no approved pharmacotherapies for NAFLD/NASH currently exist. Although the armamentarium of therapies for NASH is limited, current treatment options include life-style modification and the use of medications to treat metabolic comorbidities. This review addresses current approaches to the treatment of NAFLD/NASH, including the impact of diet, exercise, and available pharmacotherapies on the histologic features of liver injury.

Original language	English (US)
Pages (from-to)	397-412
Number of pages	16
Journal	Clinics in Liver Disease
Volume	27
Issue number	2
DOIs	https://doi.org/10.1016/j.cld.2023.01.008
State	Published - May 2023

Keywords

Fibrosis
Life-style modification
Metabolic syndrome
Nonalcoholic fatty liver disease
Nonalcoholic steatohepatitis
Non-alcoholic Fatty Liver Disease/drug therapy
Diet
Liver Cirrhosis/pathology
Humans
Liver Neoplasms

ASJC Scopus subject areas

Hepatology

Access to Document

10.1016/j.cld.2023.01.008

Cite this

@article{32b76d72ed384b86b0c506ba7ecb7929,

title = "Current Treatment Options, Including Diet, Exercise, and Medications: The Impact on Histology",

abstract = "Paralleling the rise in obesity and diabetes, nonalcoholic fatty liver disease (NAFLD) is now the most prevalent chronic liver disease worldwide. Nonalcoholic steatohepatitis (NASH), the progressive form of NAFLD, may progress to cirrhosis, hepatic decompensation, and hepatocellular carcinoma. Despite its public health treat, no approved pharmacotherapies for NAFLD/NASH currently exist. Although the armamentarium of therapies for NASH is limited, current treatment options include life-style modification and the use of medications to treat metabolic comorbidities. This review addresses current approaches to the treatment of NAFLD/NASH, including the impact of diet, exercise, and available pharmacotherapies on the histologic features of liver injury.",

keywords = "Fibrosis, Life-style modification, Metabolic syndrome, Nonalcoholic fatty liver disease, Nonalcoholic steatohepatitis, Non-alcoholic Fatty Liver Disease/drug therapy, Diet, Liver Cirrhosis/pathology, Humans, Liver Neoplasms",

author = "Mazen Noureddin and Abdelmalek, {Manal F.}",

year = "2023",

month = may,

doi = "10.1016/j.cld.2023.01.008",

language = "English (US)",

volume = "27",

pages = "397--412",

journal = "Clinics in Liver Disease",

issn = "1089-3261",

publisher = "W.B. Saunders Ltd",

number = "2",

}

TY - JOUR

T1 - Current Treatment Options, Including Diet, Exercise, and Medications

T2 - The Impact on Histology

AU - Noureddin, Mazen

AU - Abdelmalek, Manal F.

PY - 2023/5

Y1 - 2023/5

N2 - Paralleling the rise in obesity and diabetes, nonalcoholic fatty liver disease (NAFLD) is now the most prevalent chronic liver disease worldwide. Nonalcoholic steatohepatitis (NASH), the progressive form of NAFLD, may progress to cirrhosis, hepatic decompensation, and hepatocellular carcinoma. Despite its public health treat, no approved pharmacotherapies for NAFLD/NASH currently exist. Although the armamentarium of therapies for NASH is limited, current treatment options include life-style modification and the use of medications to treat metabolic comorbidities. This review addresses current approaches to the treatment of NAFLD/NASH, including the impact of diet, exercise, and available pharmacotherapies on the histologic features of liver injury.

AB - Paralleling the rise in obesity and diabetes, nonalcoholic fatty liver disease (NAFLD) is now the most prevalent chronic liver disease worldwide. Nonalcoholic steatohepatitis (NASH), the progressive form of NAFLD, may progress to cirrhosis, hepatic decompensation, and hepatocellular carcinoma. Despite its public health treat, no approved pharmacotherapies for NAFLD/NASH currently exist. Although the armamentarium of therapies for NASH is limited, current treatment options include life-style modification and the use of medications to treat metabolic comorbidities. This review addresses current approaches to the treatment of NAFLD/NASH, including the impact of diet, exercise, and available pharmacotherapies on the histologic features of liver injury.

KW - Fibrosis

KW - Life-style modification

KW - Metabolic syndrome

KW - Nonalcoholic fatty liver disease

KW - Nonalcoholic steatohepatitis

KW - Non-alcoholic Fatty Liver Disease/drug therapy

KW - Diet

KW - Liver Cirrhosis/pathology

KW - Humans

KW - Liver Neoplasms

UR - http://www.scopus.com/inward/record.url?scp=85150378957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85150378957&partnerID=8YFLogxK

U2 - 10.1016/j.cld.2023.01.008

DO - 10.1016/j.cld.2023.01.008

M3 - Review article

C2 - 37024215

AN - SCOPUS:85150378957

SN - 1089-3261

VL - 27

SP - 397

EP - 412

JO - Clinics in Liver Disease

JF - Clinics in Liver Disease

IS - 2

ER -

Current Treatment Options, Including Diet, Exercise, and Medications: The Impact on Histology

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this